Antioxidants/*therapeutic use Databases Factual Dietary Supplements Humans Randomized Controlled Trials as Topic Risk Urinary Bladder Neoplasms/pathology/*prevention & control Vitamins/*therapeutic use beta Carotene/therapeutic use Antioxidant Bladder Cancer Meta-Analysis Randomized Controlled Trials Vitamin

Bladder cancer gene genetic susceptibility genetic variant metaanalysis pathway

Carcinoma Transitional Cell/pathology/*surgery Cystectomy/*methods Humans Kaplan-Meier Estimate Neoplasm Recurrence Local Risk Factors Urethra/*pathology Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Neobladder Radical cystectomy Urethral recurrence Urothelial carcinoma

Fluorodeoxyglucose F18 Humans Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis/diagnosis/*diagnostic imaging/pathology Neoplasm Staging/methods Positron Emission Tomography Computed Tomography/*methods ROC Curve Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/pathology/surgery Bladder cancer F-18 fluorodeoxyglucose Lymph node Positron emission tomography/computed tomography Staging

Adjuvants Immunologic/administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Bayes Theorem Disease Progression Humans Immunotherapy/*methods Incidence Neoplasm Recurrence Local/drug therapy Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy Intravesical bacillus Calmette–Guerin efficacy maintenance non-muscle-invasive bladder cancer side effects

Cystectomy/*methods Disease-Free Survival Humans Lymphatic Metastasis *Margins of Excision Neoplasm Recurrence Local Neoplasm Staging Prognosis Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery bladder cancer meta-analysis outcome radical cystectomy surgical margin status

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Bladder cancer biomarker protein urine

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage Humans Neoadjuvant Therapy Neoplasm Invasiveness Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Bladder cancer Chemotherapy Neoadjuvant Platinum Survival article.

Area Under Curve Biomarkers Tumor/*urine Case-Control Studies Humans Odds Ratio RNA Long Noncoding/*urine Sensitivity and Specificity Software Urinary Bladder Neoplasms/*diagnosis/ethnology/genetics/urine Uca1 biomarker bladder cancer noninvasive diagnosis urinary marker

ImmunoCyt test bladder cancer cytology

Cystectomy/*methods Humans Prognosis *Quality of Life Urinary Bladder Neoplasms/*surgery Bladder cancer Continent urinary diversion Incontinent urinary diversion Quality of life Radical cystectomy

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

Adult Aged Aged 80 and over Female Humans Middle Aged *Parity Risk Assessment Urinary Bladder Neoplasms/*epidemiology/etiology/physiopathology Bladder cancer Meta-analysis Parity Women’s health

Carcinogenesis Carcinoma Renal Cell/*epidemiology/mortality Humans Kidney Neoplasms/*epidemiology/mortality Tobacco Smoking/*adverse effects Urinary Bladder Neoplasms/*epidemiology/mortality Bladder cancer Kidney cancer Tobacco smoking

Humans *Hyperthermia Induced Treatment Outcome Urinary Bladder Neoplasms/*therapy Bladder cancer chemohyperthermia radiohyperthermia regional hyperthermia therapy urothelial carcinoma

Diet Exercise Female Humans Male Meta-Analysis as Topic Occupational Exposure/adverse effects Occupations Risk Factors Smoking/adverse effects Urinary Bladder Neoplasms/*etiology/prevention & control Bladder cancer Lifestyle Obesity Occupation Prevention Smoking

Aminolevulinate and transurethral resection bladder cancer fluorescence hexaminolevulinate photodynamic diagnosis progression

Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab